Curis (NASDAQ:CRIS) Rating Increased to Hold at Zacks Research

Curis (NASDAQ:CRIS) was upgraded by equities researchers at Zacks Research from a “strong sell” rating to a “hold” rating in a report issued on Monday,Zacks.com reports.

Other research analysts also recently issued research reports about the stock. Wall Street Zen raised shares of Curis to a “hold” rating in a research report on Saturday, March 28th. HC Wainwright reaffirmed a “buy” rating and issued a $340.00 target price on shares of Curis in a report on Friday, March 20th. Finally, Weiss Ratings reiterated a “sell (e+)” rating on shares of Curis in a research note on Monday, April 20th. One investment analyst has rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, Curis has an average rating of “Hold” and a consensus target price of $340.00.

Curis Stock Down 2.1%

Shares of Curis stock opened at $4.65 on Monday. Curis has a 12-month low of $3.61 and a 12-month high of $39.00. The stock has a market cap of $9.07 million, a P/E ratio of -0.20 and a beta of 3.08. The business’s 50 day moving average is $8.67 and its 200-day moving average is $14.10.

Curis (NASDAQ:CRIS) last released its earnings results on Tuesday, May 12th. The biotechnology company reported ($25.00) earnings per share for the quarter, missing the consensus estimate of ($6.53) by ($18.47). On average, sell-side analysts expect that Curis will post -25.5 EPS for the current year.

Institutional Trading of Curis

A number of hedge funds have recently modified their holdings of the stock. Maverick Capital Ltd. boosted its holdings in shares of Curis by 7.8% during the 2nd quarter. Maverick Capital Ltd. now owns 681,381 shares of the biotechnology company’s stock worth $1,472,000 after buying an additional 49,554 shares during the period. Squarepoint Ops LLC lifted its position in Curis by 17.9% during the third quarter. Squarepoint Ops LLC now owns 59,140 shares of the biotechnology company’s stock worth $98,000 after acquiring an additional 8,973 shares during the last quarter. Armistice Capital LLC lifted its position in Curis by 8.7% during the third quarter. Armistice Capital LLC now owns 978,190 shares of the biotechnology company’s stock worth $1,624,000 after acquiring an additional 78,265 shares during the last quarter. Northwestern Mutual Wealth Management Co. boosted its holdings in shares of Curis by 2,883,237.5% during the fourth quarter. Northwestern Mutual Wealth Management Co. now owns 230,667 shares of the biotechnology company’s stock worth $228,000 after acquiring an additional 230,659 shares during the period. Finally, Renaissance Technologies LLC grew its position in shares of Curis by 37.3% in the fourth quarter. Renaissance Technologies LLC now owns 240,917 shares of the biotechnology company’s stock valued at $238,000 after purchasing an additional 65,404 shares during the last quarter. Institutional investors and hedge funds own 29.97% of the company’s stock.

About Curis

Curis, Inc is a biotechnology company focused on the discovery, development and commercialization of targeted small molecule and antibody therapeutics for the treatment of cancer. The company’s research centers on exploiting key signaling pathways and tumor microenvironment interactions to develop compounds with the potential to address unmet medical needs. Curis’ proprietary pipeline includes multiple programs at various stages of clinical and preclinical development, reflecting its emphasis on innovative oncology drug candidates.

Among Curis’ lead assets is CA-4948, an oral inhibitor of interleukin-1 receptor–associated kinase 4 (IRAK4) partnered with Ikena Oncology, which is being evaluated in hematologic malignancies and solid tumors.